In this casual chat, we hear from investors that traditionally focus on technology companies: how do they think differently and what would make them consider working with a life science player?

In the Nordics, we are sitting on a vast number of viable data sources – and data, as we know, is key to our industry’s ability to thrive. As such, we must cooperate to better align, integrate, and use our data sources in a protected and patient-centric way that also supports industry participation. In this session, we look at examples of successful collaboration models, at how data helps to drive the value of an asset, at the importance of industry, and at the reciprocal requirement to address and articulate societal value.

This presentation session is dedicated to those who have created a unique way of integrating, using, or developing data in their research or business models.

The human microbiome is considered to be a counterpart to the human genome, with the number of genes in our microbiome outnumbering the genes in our genome by 100 to 1. We also know that understanding and thus balancing our microbiome is vital to human health, and that our microbes are impacted on a community rather than individual-level. In this session, we will hear from some of the world’s leaders on the state of microbiome research, as well as how research findings are impacting our approach to disease development and treatment.

A collaborative mindset is required for success at all levels of scientific and health care development. However, the hesitancy towards working with industry still exists, particularly amongst legacy systems. How do we tackle such challenges?

By 2030, the population is expected to exceed 8.5 billion, with some countries preparing for an average life expectancy of 90+ years. Increasing age is partnered with a growing prevalence of non-communicable diseases and chronic conditions. Likewise, the demographic shift comes with exponential costs to the health care system and societal challenges for how to spend additional years in declining health. In this session, we look at some of the global and Nordic leaders across aging-related fields, how they are tackling these issues, and what is still needed for longevity to equate quality of life.

This presentation session is dedicated to those who are thinking outside-the-box when it comes to how they aim to or have succeeded in partnering their research or products.

In the digital age, there  now exists a cross-industry playground that defies traditional thinking in life sciences. More than ever, we need to understand what it means to defy risks and charge towards creativity. What do we need to know and how are tech giants changing the game?

Approaching the financial community can be a daunting task, one made greater if we don’t know our particular audiencewell enough. In this session, we focus on hunting intelligently. We highlight different ways of thinking between varying types of investors and then deep-dive into the venture world to better understand what venture capital really is, what are its pros and cons, how to find the right match, and what to know about a rejection. Expect a dialogue, so come prepared with your questions!

This presentation session is dedicated to service-oriented companies with a strong scientific base and a unique offering to share with the life science community.

CROs can get a ‘bad rap’ across some parts of our industry. Why is that, and how can we open the dialogues to do business when sales meets science? Likewise, as a small company, how do you know which CRO is right for you?

Tackling global health challenges requires that we move from ‘reactive’ to  ‘proactive’ care, and that we personalize our approach. The practice of evidence-based medicine and the continued identification of new biomarkers are vital steps in improving disease diagnosis, improving the safety and efficacy of existing medicines, and in developing new medicines and targeted therapies. In this session, we discuss the needs and challenges from both industry and financial viewpoints.

In the world of exponential data and digital disruption, there are more players involved in R&D than ever before. Traditional business models across the drug discovery and development value chain are, therefore, transitioning at an increasingly rapid pace. In this session, we take a look at the new playground: who is involved, how are they working together, and what does this mean for the future of clinical trials from academic, pharma, technology, and regulatory perspectives.

This presentation session is dedicated to technologies that offer a new approach for life sciences – particular those that, in earlier years, may not have been seen as relevant to the sector.